EP3829606A4 - Anti-cd79 antibodies and their uses - Google Patents
Anti-cd79 antibodies and their uses Download PDFInfo
- Publication number
- EP3829606A4 EP3829606A4 EP19868305.4A EP19868305A EP3829606A4 EP 3829606 A4 EP3829606 A4 EP 3829606A4 EP 19868305 A EP19868305 A EP 19868305A EP 3829606 A4 EP3829606 A4 EP 3829606A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862740655P | 2018-10-03 | 2018-10-03 | |
PCT/US2019/054372 WO2020072705A1 (en) | 2018-10-03 | 2019-10-03 | Anti-cd79 antibodies and their uses |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3829606A1 EP3829606A1 (en) | 2021-06-09 |
EP3829606A4 true EP3829606A4 (en) | 2022-07-06 |
Family
ID=70052001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19868305.4A Pending EP3829606A4 (en) | 2018-10-03 | 2019-10-03 | Anti-cd79 antibodies and their uses |
Country Status (7)
Country | Link |
---|---|
US (2) | US11078276B2 (en) |
EP (1) | EP3829606A4 (en) |
JP (1) | JP2022513338A (en) |
KR (1) | KR20210071987A (en) |
CN (1) | CN113194966A (en) |
AU (1) | AU2019355115A1 (en) |
WO (1) | WO2020072705A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3829606A4 (en) * | 2018-10-03 | 2022-07-06 | Nepenthe Bioscience, LLC | Anti-cd79 antibodies and their uses |
CA3231174A1 (en) * | 2021-08-02 | 2023-02-09 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-cd79bxcd3 bispecific antibody and use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009012256A1 (en) * | 2007-07-16 | 2009-01-22 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
US20110135667A1 (en) * | 2007-07-16 | 2011-06-09 | Genentech, Inc. | Anti-cd79b antibodies and immunoconjugates and methods of use |
WO2016090210A1 (en) * | 2014-12-05 | 2016-06-09 | Genentech, Inc. | ANTI-CD79b ANTIBODIES AND METHODS OF USE |
WO2017009474A1 (en) * | 2015-07-16 | 2017-01-19 | Ucb Biopharma Sprl | Antibody molecules which bind cd79 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ES2732504T3 (en) * | 2008-10-29 | 2019-11-22 | Circular Commitment Company | Procedures and agents for the diagnosis and treatment of hepatocellular carcinoma |
AU2015207936A1 (en) * | 2009-05-13 | 2015-08-27 | Genzyme Corporation | Anti-human CD52 immunoglobulins |
GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
WO2016049214A1 (en) * | 2014-09-23 | 2016-03-31 | Genentech, Inc. | METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES |
WO2016062898A1 (en) * | 2014-10-24 | 2016-04-28 | Bcrt Holding Bv | T cell-based immunotherapeutics |
WO2016086196A2 (en) * | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
CN108025066B (en) * | 2015-05-12 | 2022-04-12 | Synt免疫公司 | Humanized affinity matured anti-FcRn antibodies |
CA3001859A1 (en) * | 2015-10-16 | 2017-04-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
MX2018015265A (en) * | 2016-06-07 | 2019-09-06 | Macrogenics Inc | Methods for the use of cd32b x cd79b-binding molecules in the treatment of inflammatory diseases and disorders. |
EP3829606A4 (en) * | 2018-10-03 | 2022-07-06 | Nepenthe Bioscience, LLC | Anti-cd79 antibodies and their uses |
-
2019
- 2019-10-03 EP EP19868305.4A patent/EP3829606A4/en active Pending
- 2019-10-03 CN CN201980058484.6A patent/CN113194966A/en active Pending
- 2019-10-03 KR KR1020217010355A patent/KR20210071987A/en active Search and Examination
- 2019-10-03 WO PCT/US2019/054372 patent/WO2020072705A1/en unknown
- 2019-10-03 AU AU2019355115A patent/AU2019355115A1/en active Pending
- 2019-10-03 US US16/591,617 patent/US11078276B2/en active Active
- 2019-10-03 JP JP2021543979A patent/JP2022513338A/en active Pending
-
2021
- 2021-07-22 US US17/382,821 patent/US20210355214A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009012256A1 (en) * | 2007-07-16 | 2009-01-22 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
US20110135667A1 (en) * | 2007-07-16 | 2011-06-09 | Genentech, Inc. | Anti-cd79b antibodies and immunoconjugates and methods of use |
WO2016090210A1 (en) * | 2014-12-05 | 2016-06-09 | Genentech, Inc. | ANTI-CD79b ANTIBODIES AND METHODS OF USE |
WO2017009474A1 (en) * | 2015-07-16 | 2017-01-19 | Ucb Biopharma Sprl | Antibody molecules which bind cd79 |
Non-Patent Citations (3)
Title |
---|
IAN R. HARDY ET AL: "Anti-CD79 Antibody Induces B Cell Anergy That Protects against Autoimmunity", THE JOURNAL OF IMMUNOLOGY, vol. 192, no. 4, 17 January 2014 (2014-01-17), US, pages 1641 - 1650, XP055699300, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1302672 * |
LI YONGMEI ET AL: "B Cell Depletion with Anti-CD79 mAbs Ameliorates Autoimmune Disease in MRL/ lpr Mice", THE JOURNAL OF IMMUNOLOGY, vol. 181, no. 5, 1 September 2008 (2008-09-01), US, pages 2961 - 2972, XP055925082, ISSN: 0022-1767, Retrieved from the Internet <URL:https://www.jimmunol.org/content/jimmunol/181/5/2961.full.pdf> DOI: 10.4049/jimmunol.181.5.2961 * |
See also references of WO2020072705A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2019355115A1 (en) | 2021-03-04 |
KR20210071987A (en) | 2021-06-16 |
WO2020072705A1 (en) | 2020-04-09 |
US20200109198A1 (en) | 2020-04-09 |
CN113194966A (en) | 2021-07-30 |
US20210355214A1 (en) | 2021-11-18 |
JP2022513338A (en) | 2022-02-07 |
US11078276B2 (en) | 2021-08-03 |
EP3829606A1 (en) | 2021-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3759143A4 (en) | Anti-tigit antibodies and uses thereof | |
EP3740224A4 (en) | Anti-lilrb antibodies and uses thereof | |
EP3762030A4 (en) | Anti-cd73 antibodies and uses thereof | |
EP3838289A4 (en) | Anti-tigit antibody and uses thereof | |
EP3383916A4 (en) | Anti-cd73 antibodies and uses thereof | |
EP3625263A4 (en) | Anti-galectin-9 antibodies and uses thereof | |
EP3797124A4 (en) | Anti-ror1 antibody and use thereof | |
EP3596119A4 (en) | Anti-phf-tau antibodies and uses thereof | |
EP3389702A4 (en) | Anti-lag-3 antibodies and uses thereof | |
EP3891183A4 (en) | Anti-claudin antibodies and uses thereof | |
EP3802612A4 (en) | Anti-b7-h3 antibody and use thereof | |
EP3875484A4 (en) | Cll1-targeting antibody and application thereof | |
EP3918323A4 (en) | Anti-gal3 antibodies and uses thereof | |
EP3735427A4 (en) | Anti-mct1 antibodies and uses thereof | |
EP3645563A4 (en) | Anti-fam19a5 antibodies and uses thereof | |
EP3790586A4 (en) | Anti-dll3 antibodies and uses thereof | |
EP3997127A4 (en) | Dll3-targeting antibodies and uses thereof | |
EP3733702A4 (en) | Anti-lag-3 antibody and uses thereof | |
EP3562508A4 (en) | Anti-lair1 antibodies and their uses | |
EP3768317A4 (en) | Anti-il-27 antibodies and uses thereof | |
EP3672987A4 (en) | Anti-apelin antibodies and uses thereof | |
EP3904382A4 (en) | Anti-il-23p19 antibody and uses thereof | |
EP3894440A4 (en) | Anti-il-27 antibodies and uses thereof | |
EP3681912A4 (en) | Axl-specific antibodies and uses thereof | |
EP3675898A4 (en) | Anti-lag-3 antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210218 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220607 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 19/00 20060101ALI20220601BHEP Ipc: C07K 16/28 20060101ALI20220601BHEP Ipc: A61K 39/395 20060101ALI20220601BHEP Ipc: A61K 35/17 20150101AFI20220601BHEP |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20231122 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240513 |